Explore more publications!
Palestine Health Report
Got News to Share?

Palestine Health Report: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Palestine Health Report.

October 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

December 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31

Press releases published on December 2, 2025

Predictive Oncology Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
December 2, 2025

Predictive Oncology Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement

Indeterminate GlobeNewswire
Immutep to Present New Data from AIPAC-003 Phase II at the 2025 San Antonio Breast Cancer Symposium
December 2, 2025

Immutep to Present New Data from AIPAC-003 Phase II at the 2025 San Antonio Breast Cancer Symposium

Indeterminate GlobeNewswire
Electra Therapeutics Presents SURPASS Pivotal ELA026 Study Design and Highlights the Critical Unmet Need in Secondary Hemophagocytic Lymphohistiocytosis (sHLH) at the ASH 2025 Annual Meeting
December 2, 2025

Electra Therapeutics Presents SURPASS Pivotal ELA026 Study Design and Highlights the Critical Unmet Need in Secondary Hemophagocytic Lymphohistiocytosis (sHLH) at the ASH 2025 Annual Meeting

Indeterminate GlobeNewswire
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on December 4
December 2, 2025

Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on December 4

Indeterminate GlobeNewswire
Pacira BioSciences Announces Results From 12-Month Pilot Study Demonstrating Favorable Safety and Significant Improvements in Pain With iovera° Compared to Radiofrequency Ablation in Chronic Low Back Pain
December 2, 2025

Pacira BioSciences Announces Results From 12-Month Pilot Study Demonstrating Favorable Safety and Significant Improvements in Pain With iovera° Compared to Radiofrequency Ablation in Chronic Low Back Pain

Indeterminate GlobeNewswire
Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology
December 2, 2025

Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology

Indeterminate GlobeNewswire
Oncotelic and Sapu Nano Unveils Broad-Applicability Deciparticle™ Nanomedicine Platform Capable of Formulating Multiple Hydrophobic Peptide, Macrolide, and Polyketide Drugs
December 2, 2025

Oncotelic and Sapu Nano Unveils Broad-Applicability Deciparticle™ Nanomedicine Platform Capable of Formulating Multiple Hydrophobic Peptide, Macrolide, and Polyketide Drugs

Indeterminate GlobeNewswire
HealthLynked Expands Board of Directors With Addition of Two Leading Insurance Executives: Chris G. Pulos of Marsh McLennan and Jason Bishara of NSI Insurance
December 2, 2025

HealthLynked Expands Board of Directors With Addition of Two Leading Insurance Executives: Chris G. Pulos of Marsh McLennan and Jason Bishara of NSI Insurance

Indeterminate GlobeNewswire
NewGen Reports Nine-Month 2025 Results with Balance Sheet Strengthened to $66.75 Net Asset Value Per Share
December 2, 2025

NewGen Reports Nine-Month 2025 Results with Balance Sheet Strengthened to $66.75 Net Asset Value Per Share

Indeterminate GlobeNewswire
Three Trailblazing Women in Health Care Honoured with the Medal of the Member of the National Assembly
December 2, 2025

Three Trailblazing Women in Health Care Honoured with the Medal of the Member of the National Assembly

Indeterminate GlobeNewswire
Trois femmes pionnières en soins de santé récompensées par une Médaille de l’Assemblée nationale
December 2, 2025

Trois femmes pionnières en soins de santé récompensées par une Médaille de l’Assemblée nationale

Indeterminate GlobeNewswire
Clearmind Medicine Advances CMND-100 to Dosing Phase at Hadassah Medical Center in Ongoing Phase I/IIa Clinical Trial for Alcohol Use Disorder
December 2, 2025

Clearmind Medicine Advances CMND-100 to Dosing Phase at Hadassah Medical Center in Ongoing Phase I/IIa Clinical Trial for Alcohol Use Disorder

Indeterminate GlobeNewswire
Polyrizon Announces Successful Completion of Key Manufacturing Upscaling Milestone for Its Nasal Spray Platform
December 2, 2025

Polyrizon Announces Successful Completion of Key Manufacturing Upscaling Milestone for Its Nasal Spray Platform

Indeterminate GlobeNewswire
Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhD
December 2, 2025

Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhD

Indeterminate GlobeNewswire
NRx Pharmaceuticals (NASDAQ: NRXP) and HOPE Therapeutics to Host Corporate Update Call
December 2, 2025

NRx Pharmaceuticals (NASDAQ: NRXP) and HOPE Therapeutics to Host Corporate Update Call

Indeterminate GlobeNewswire
BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025
December 2, 2025

BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025

Indeterminate GlobeNewswire
Nkarta to Participate in Evercore Healthcare Conference
December 2, 2025

Nkarta to Participate in Evercore Healthcare Conference

Indeterminate GlobeNewswire
Pluristyx Launches Organoid COMMONS, Uniting Industry Leaders to Revolutionize Drug Discovery
December 2, 2025

Pluristyx Launches Organoid COMMONS, Uniting Industry Leaders to Revolutionize Drug Discovery

Indeterminate GlobeNewswire
Ventyx Provides Clinical and Corporate Updates
December 2, 2025

Ventyx Provides Clinical and Corporate Updates

Indeterminate GlobeNewswire
Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK® in Japan to Reduce Cisplatin-Induced Hearing Loss
December 2, 2025

Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK® in Japan to Reduce Cisplatin-Induced Hearing Loss

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions